Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expense/(income) | ||||
| Provision for changes in expected cash flows from financial royalty assets | 268,216 | (203,938) | 70,732 | (331,078) |
| Provision for credit losses on unfunded commitments | 13,068 | 92,535 | 9,368 | 92,535 |
| Research and development funding expense | 97,851 | 300,500 | 137,641 | 351,000 |
| General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4) | 161,887 | 179,769 | 321,377 | 290,475 |
| Financial royalty asset impairment | — | — | 69,443 | — |
| Total operating expense, net | 541,022 | 368,866 | 608,561 | 402,932 |
| Operating income | 133,119 | 209,799 | 696,156 | 743,980 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's R&D?
- Royalty Pharma (RPRX) reported R&D of $97.85M in Q2 2026.
- How has Royalty Pharma's R&D changed year-over-year?
- Royalty Pharma's R&D decreased by 67.4% year-over-year, from $300.5M to $97.85M.
- What is the long-term trend for Royalty Pharma's R&D?
- Over 4 years (2021 to 2025), Royalty Pharma's R&D has grown at a 22.6% compound annual growth rate (CAGR), from $200.08M to $452M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Royalty Pharma's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude